Baird maintains Twist Bioscience at Outperform, lowers price target to $135 from $187

What happened

Baird kept its Outperform rating on Twist Bioscience but cut its price target to $135 from $187, a 27.8% decrease. The revised target implies 18.2% upside from the stock’s November 12 closing price of $114.22.

Confirmed

Global impact / market context

The lower target signals that Baird now sees less potential value for Twist than before, even while retaining its positive rating. If investors act on that view, demand for the shares could be affected; the article reports no actual market reaction.

Analyst inference

The target remains above the stated November 12 close, so Baird’s view still implies possible share-price gains from that reference point. However, the cut indicates a less optimistic valuation than its previous target; no company results or reasons for the change are given.

Analyst inference

What to watch

1. Check for any further Baird rating or target changes, which would show whether the analyst’s view continues to shift after this reduction. Analyst inference
2. Compare future company updates with the assumptions behind the $135 target, if those assumptions become available; the article does not explain Baird’s reasoning. Analyst inference
3. Watch how Twist shares trade relative to the $114.22 November 12 close and the $135 target; the article provides no subsequent trading data. Analyst inference

Evidence

• Original source link unavailable